Preventive strategies in chronic liver disease: part I. Alcohol, vaccines, toxic medications and supplements, diet and exercise.
暂无分享,去创建一个
[1] B. Balkau,et al. A multicenter, controlled trial of ursodiol for the treatment of primary biliary cirrhosis. UDCA-PBC Study Group. , 1991, The New England journal of medicine.
[2] K. Reddy,et al. Hepatitis C Virus Genotypes in the United States: Epidemiology, Pathogenicity, and Response to Interferon Therapy , 1996, Annals of Internal Medicine.
[3] P. O'Connor,et al. Patients with alcohol problems. , 1998, The New England journal of medicine.
[4] W. Schaffner,et al. Adult Immunizations , 1996, Annals of Internal Medicine.
[5] H. Zimmerman,et al. Acetaminophen (paracetamol) hepatotoxicity with regular intake of alcohol: Analysis of instances of therapeutic misadventure , 1995, Hepatology.
[6] E. Schiff,et al. Hepatitis C and Alcohol , 2003, Alcohol research & health : the journal of the National Institute on Alcohol Abuse and Alcoholism.
[7] B. McMahon,et al. Safety and immunogenicity of hepatitis A vaccine in patients with chronic liver disease , 1998, Hepatology.
[8] W. Irish,et al. Response to interferon α therapy is influenced by the iron content of the liver , 1994 .
[9] D. V. van Thiel,et al. Response to interferon alpha therapy is influenced by the iron content of the liver. , 1994, Journal of hepatology.
[10] Lewis Jh,et al. Hepatotoxicity of drugs used in the treatment of gastrointestinal disorders. , 1995 .
[11] W. M. Lee,et al. Drug-induced hepatotoxicity. , 1995, The New England journal of medicine.
[12] E. Keeffe. Is hepatitis A more severe in patients with chronic hepatitis B and other chronic liver diseases? , 1995, The American journal of gastroenterology.
[13] D. Francis. The public's health unprotected. Reversing a decade of underutilization of hepatitis B vaccine. , 1995, JAMA.
[14] Jill P. Smith,et al. Ibuprofen-induced hepatotoxicity in patients with chronic hepatitis c: a case series , 1998, American Journal of Gastroenterology.
[15] K. Reddy,et al. Hepatitis C virus genotypes in the United States: epidemiology, pathogenicity, and response to interferon therapy. Collaborative Study Group. , 1996, Annals of internal medicine.
[16] Alan D. Lopez,et al. Alcohol consumption and mortality among middle-aged and elderly U.S. adults. , 1997, The New England journal of medicine.
[17] M. Friedman,et al. Relationship between liver biochemical tests and dietary intake in patients with liver disease. , 1994, Journal of clinical gastroenterology.
[18] G. Davis. Combination treatment with interferon and ribavirin for chronic hepatitis C. , 1999, Clinics in liver disease.
[19] S. Vento,et al. Fulminant hepatitis associated with hepatitis A virus superinfection in patients with chronic hepatitis C , 2000, Journal of viral hepatitis.
[20] S. L. Murphy. Deaths: final data for 1998. , 2000, National vital statistics reports : from the Centers for Disease Control and Prevention, National Center for Health Statistics, National Vital Statistics System.
[21] K. Tanikawa,et al. Therapeutic effects of restricted diet and exercise in obese patients with fatty liver. , 1997, Journal of hepatology.
[22] E. Schiff,et al. Hepatic iron concentration as a predictor of response to interferon alfa therapy in chronic hepatitis C. , 1995, Gastroenterology.
[23] M A Gerber,et al. The natural history of community-acquired hepatitis C in the United States. The Sentinel Counties Chronic non-A, non-B Hepatitis Study Team. , 1992, The New England journal of medicine.
[24] G. Corrao,et al. Independent and combined action of hepatitis C virus infection and alcohol consumption on the risk of symptomatic liver cirrhosis. , 1998, Hepatology.
[25] L. Gallagher. Hepatitis B. , 2016, Journal.
[26] P. Schirmacher,et al. Viral and host factors in the prediction of response to interferon‐α therapy in chronic hepatitis C after long‐term follow‐up , 1998, Journal of viral hepatitis.
[27] Miriam J. Alter. Epidemiology of hepatitis C. , 1996 .
[28] O. Senofonte,et al. Iron overload in patients with chronic viral hepatitis: how common is it? , 1997, The American journal of gastroenterology.
[29] H. Rosen,et al. Milk Thistle (Silybum marianum) for the Therapy of Liver Disease , 1998, American Journal of Gastroenterology.
[30] R. Scheig. Effects of ethanol on the liver. , 1970, The American journal of clinical nutrition.
[31] R. Steele. Fulminant hepatitis associated with hepatitis A virus superinfection in patients with chronic hepatitis C. , 1998, Clinical pediatrics.
[32] B. Bell. Hepatitis A vaccine. , 2002, Seminars in pediatric infectious diseases.
[33] R. Hanson,et al. The natural history of nonalcoholic steatohepatitis: A follow‐up study of forty‐two patients for up to 21 years , 1990, Hepatology.
[34] A. McCullough,et al. Alcoholic liver disease: proposed recommendations for the American College of Gastroenterology , 1998, American Journal of Gastroenterology.
[35] M. Yano,et al. Improvement of serum aminotransferase levels after phlebotomy in patients with chronic active hepatitis C and excess hepatic iron. , 1994, The American journal of gastroenterology.
[36] L. Jeffers,et al. Hepatitis C and alcohol. , 1999, Alcoholism, clinical and experimental research.
[37] G. Gores,et al. Ursodeoxycholic acid or clofibrate in the treatment of non‐alcohol‐induced steatohepatitis: A pilot study , 1996, Hepatology.
[38] J. Hoofnagle,et al. Measurements of iron status in patients with chronic hepatitis. , 1992, Gastroenterology.
[39] J. Carson,et al. Toxicity of nonsteroidal anti-inflammatory drugs. An overview of the epidemiological evidence. , 1993, Drugs.